Cameron is a Client Partner in the Competitive Strategy practice at Prescient, where he leads engagements for global pharmaceutical and biotechnology clients across cell and gene therapy, oncology, immunology, nephrology and cardio-metabolic disease. He oversees multi-workstream advisory programmes, contributes to the practice’s long-range strategy, and develops new approaches, including AI-augmented competitive intelligence methodologies, that are adopted across the wider team.
Cameron began his career as a scientist, earning his PhD in biophysical chemistry at the University of Glasgow, where he elucidated the novel structure and dynamics of a surfactant protein. He went on to spend over a decade in industry across both established firms and start-ups, in roles spanning R&D, GMP manufacturing, business development, licensing and intellectual property management. As a Protein Chemist at Piramal, he supported early antibody-drug conjugate manufacturing. As Senior Scientist at LUX Biotechnology, he led the invention, development and commercial launch of an industrial biotech diagnostic and contributed to a dental device product now on the market. He later advised life science start-ups as Principal at Brathmòr Ventures and led business development at TC BioPharm, a clinical-stage gamma delta T cell therapy company, where he developed particular expertise in cell therapy commercialisation across China and other global markets.
Cameron has contributed to bringing several marketed medicines to patients, including Seretide, Bridion and Kadcyla, and is a named inventor on multiple patent applications, two of which have been granted. His MBA dissertation at Strathclyde Business School, titled “Is the Innovation Model of the Pharmaceutical Industry Sustainable?”, reflects a long-standing interest in how the industry generates and captures value from innovation. That theme continues to shape his consulting work today, particularly around cell and gene therapy strategy, AI-enabled CI capability building, and the strategic challenges facing both established pharma and emerging biotech.
He describes himself as curious, strategic and pragmatic.
